Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PM Kishida Vows to Hasten COVID-19 Vaccinations for under Age 12
January 12, 2022
- MHLW to Revise Laws to Allow Doctors to Issue Electronic Scripts
January 11, 2022
- MHLW Eyes Evaluation Indices and Guidelines to Fuel Rollout of SaMD and Cell & Gene Therapies: Official
January 11, 2022
- Govt to Submit PMD Law Amendment Bill in Ordinary Diet Session to Introduce Emergency Approval
January 7, 2022
- Rewarding Innovation Was the Primary Goal in 2022 Reform Debate: MHLW Official
January 7, 2022
- MHLW to Reshuffle Organization by Summer to Further Support Drug Development; Economic Affairs Division to Be Renamed
January 7, 2022
- MHLW’s COVID-19 Guide Adds MSD’s Molnupiravir
January 6, 2022
- Japan’s Drug Production Down 1.9% to 9.3 Trillion Yen in 2020: MHLW
January 6, 2022
- Japan Govt to End Observational Avigan Study for COVID-19
January 5, 2022
- MHLW Finalizes Paper on Emergency Approval System, Set to Submit Bill Next Year
December 28, 2021
- 50 Million Yen Earmarked to Support API Stockpiles to Ensure Stable Supplies: MHLW FY2022 Budget
December 28, 2021
- Japan Approves Lenvima/Keytruda Pair, Opdivo Label Expansion
December 27, 2021
- Payer, Healthcare Reps Call for Stable Supply Measures for Achieving New Generic Share Target: Chuikyo
December 27, 2021
- Sakigake Status Dropped for GSK’s Biliary Tract Cancer Drug
December 27, 2021
- Second Case of TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
December 27, 2021
- Japan Does Not Recommend Ronapreve for Omicron Variant
December 27, 2021
- 145 Million Yen Allocated for 3 New Projects to Shake Off Public Distrust in Generics: MHLW FY2022 Budget
December 27, 2021
- Japan Secures 18 Million Extra Doses of Moderna Vaccines
December 27, 2021
- Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
- Regulatory Reform Panel Urges Better Trial Environment, SaMD Review
December 24, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…